MA03.06 Efficacy Results of Selective AXL Inhibitor Bemcentinib with Pembrolizumab Following Chemotherapy in Patients with NSCLCE. Felip,P. Brunsvig,Å. Helland,N. Viñolas,S. Aix,E. Carcereny,M. Dómine Gomez,J.M. Trigo Perez,E. Arriola,R. Garcia Campelo,J. Spicer,J. Thompson,A.L. Ortega Granados,R. Holt, D. Smethurst,J. Lorens,M. Shoaib,A. Siddiqui, J. Schoelermann, K. Lorens,E. Schmidt,M.J. Chisamore,M. KrebsJOURNAL OF THORACIC ONCOLOGY（2019）引用 3|浏览62暂无评分关键词bemcentinib,AXL,PembrolizumabAI 理解论文溯源树样例生成溯源树，研究论文发展脉络Chat Paper正在生成论文摘要
